PTC Therapeutics, Inc. (PTCT)

Market Cap	3.81B
Revenue (ttm)	900.66M
Net Income (ttm)	-453.20M
Shares Out	77.13M
EPS (ttm)	-5.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	648,880
Open	50.01
Previous Close	50.01
Day's Range	48.60 - 51.22
52-Week Range	23.58 - 54.16
Beta	0.62
Analysts	Hold
Price Target	55.62 (+12.64%)
Earnings Date	Feb 27, 2025

About PTCT

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pip...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2013
• Employees: 1,055
• Stock Exchange: NASDAQ
• Ticker Symbol: PTCT
• Website: https://www.ptcbio.com

Financial Performance

In 2023, PTC Therapeutics's revenue was $937.82 million, an increase of 34.20% compared to the previous year's $698.80 million. Losses were -$626.60 million, 12.1% more than in 2022.

Analyst Forecast

According to 13 analysts, the average rating for PTCT stock is "Hold." The 12-month stock price forecast is $55.62, which is an increase of 12.64% from the latest price.

Price Target

$55.62

(12.64% upside)

Analyst Consensus: Hold